| Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors Y Yu, DS Kalinowski, Z Kovacevic, AR Siafakas, PJ Jansson, C Stefani, ... Journal of medicinal chemistry 52 (17), 5271-5294, 2009 | 455 | 2009 |
| Novel di-2-pyridyl–derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment J Yuan, DB Lovejoy, DR Richardson Blood 104 (5), 1450-1458, 2004 | 435 | 2004 |
| Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity DR Richardson, PC Sharpe, DB Lovejoy, D Senaratne, DS Kalinowski, ... Journal of medicinal chemistry 49 (22), 6510-6521, 2006 | 423 | 2006 |
| Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents DR Richardson, DS Kalinowski, S Lau, PJ Jansson, DB Lovejoy Biochimica et Biophysica Acta (BBA)-General Subjects 1790 (7), 702-717, 2009 | 330 | 2009 |
| Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and-sensitive parasites A Walcourt, M Loyevsky, DB Lovejoy, VR Gordeuk, DR Richardson The international journal of biochemistry & cell biology 36 (3), 401-407, 2004 | 320 | 2004 |
| Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes DB Lovejoy, PJ Jansson, UT Brunk, J Wong, P Ponka, DR Richardson Cancer research 71 (17), 5871-5880, 2011 | 301 | 2011 |
| Design, synthesis, and characterization of novel iron chelators: Structure− activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl … DS Kalinowski, Y Yu, PC Sharpe, M Islam, YT Liao, DB Lovejoy, N Kumar, ... Journal of medicinal chemistry 50 (15), 3716-3729, 2007 | 275 | 2007 |
| Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and … TB Chaston, DB Lovejoy, RN Watts, DR Richardson Clinical cancer research 9 (1), 402-414, 2003 | 274 | 2003 |
| Chelators at the cancer coalface: desferrioxamine to Triapine and beyond Y Yu, J Wong, DB Lovejoy, DS Kalinowski, DR Richardson Clinical Cancer Research 12 (23), 6876-6883, 2006 | 246 | 2006 |
| 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity DR Richardson, DS Kalinowski, V Richardson, PC Sharpe, DB Lovejoy, ... Journal of medicinal chemistry 52 (5), 1459-1470, 2009 | 232 | 2009 |
| Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression CK Lim, A Bilgin, DB Lovejoy, V Tan, S Bustamante, BV Taylor, ... Scientific reports 7 (1), 41473, 2017 | 224 | 2017 |
| Novel “hybrid” iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells DB Lovejoy, DR Richardson Blood, The Journal of the American Society of Hematology 100 (2), 666-676, 2002 | 223 | 2002 |
| Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts … DB Lovejoy, DM Sharp, N Seebacher, P Obeidy, T Prichard, C Stefani, ... Journal of medicinal chemistry 55 (16), 7230-7244, 2012 | 198 | 2012 |
| Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the … Z Kovacevic, S Chikhani, DB Lovejoy, DR Richardson Molecular pharmacology 80 (4), 598-609, 2011 | 188 | 2011 |
| Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity PV Bernhardt, PC Sharpe, M Islam, DB Lovejoy, DS Kalinowski, ... Journal of medicinal chemistry 52 (2), 407-415, 2009 | 187 | 2009 |
| The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action GYL Lui, P Obeidy, SJ Ford, C Tselepis, DM Sharp, PJ Jansson, ... Molecular pharmacology 83 (1), 179-190, 2013 | 140 | 2013 |
| Understanding the role of the kynurenine pathway in human breast cancer immunobiology B Heng, CK Lim, DB Lovejoy, A Bessede, L Gluch, GJ Guillemin Oncotarget 7 (6), 6506, 2016 | 134 | 2016 |
| Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators DB Lovejoy, DR Richardson Current medicinal chemistry 10 (12), 1035-1049, 2003 | 124 | 2003 |
| Identification of the di‐pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti‐tumour agents EM Becker, DB Lovejoy, JM Greer, R Watts, DR Richardson British journal of pharmacology 138 (5), 819-830, 2003 | 124 | 2003 |
| Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau KR Jacobs, CK Lim, K Blennow, H Zetterberg, P Chatterjee, RN Martins, ... Neurobiology of aging 80, 11-20, 2019 | 91 | 2019 |
